ANI Pharmaceuticals Inc (ANIP)

37.96
+0.49(+1.31%)
  • Volume:
    47,495
  • Day's Range:
    36.73 - 38.17
  • 52 wk Range:
    22.31 - 60.23

ANIP Overview

Prev. Close
37.47
Day's Range
36.73-38.17
Revenue
251.32M
Open
36.98
52 wk Range
22.31-60.23
EPS
-4.4
Volume
47,495
Market Cap
621.03M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
100,055
P/E Ratio
-
Beta
1.05
1-Year Change
24.69%
Shares Outstanding
16,283,034
Next Earnings Date
Nov 09, 2022
What is your sentiment on ANI Pharma?
or
Vote to see community's results!

ANI Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

ANI Pharmaceuticals Inc Analysis

ANI Pharmaceuticals Inc Company Profile

ANI Pharmaceuticals Inc Company Profile

Employees
369

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company that serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceuticals, including for diseases with unmet medical needs. The Company is focused on developing and manufacturing niche oncology products (anti-cancer). It has a commercial portfolio of over 101 products with a variety of indications and a portfolio of pipeline products. The Company owns the facility, which includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. It also owns a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products. Its four pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, one is located in East Windsor, New Jersey and one is located in Oakville, Ontario.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyNeutral
Technical IndicatorsBuyStrong BuyStrong BuyStrong BuyBuy
SummaryBuyStrong BuyStrong BuyStrong BuyNeutral
  • AANI Pharmaceuticals annuncia l'accettazione da parte della FDA del nuovo farmaco supplementare Cortrophin® Gel purificato per indicazioni multiple tra cui sclerosi multipla, artrite reumatoide e sindrome nefrosica 31/08/2021
    0
    • up & down today
      0
      • someone inside?
        0